Psma2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | Proteasome Subunit Alpha Type 2 |
| Gene | PSMA2 |
| UniProt ID | P25787 |
| Complex | 20S core particle of the proteasome |
| Localization | Cytoplasm and nucleus |
| Major Function | Alpha-ring architecture and substrate-gate control |
PSMA2 encodes alpha type 2, a structural component of the 20S proteasome core. Together with PSMA5 and other alpha subunits, PSMA2 forms the outer rings that regulate substrate entry into the proteolytic chamber.[1][2] In neurons, this gatekeeping function is critical for managing high protein-turnover demand and limiting accumulation of aggregation-prone proteins linked to Alzheimer's Disease, Parkinson's Disease, and related disorders.[2:1][3]
The 20S proteasome contains two alpha rings and two beta rings; catalytic cleavage occurs in beta subunits, while alpha subunits such as PSMA2 control access and structural integrity.[1:1][4] Conformational coupling between alpha rings and regulatory particles (19S/PA28) determines when ubiquitinated substrates are admitted for degradation.[4:1][5]
PSMA2 therefore contributes indirectly to catalytic efficiency by:
Defects in these structural steps can reduce effective proteasome throughput without direct mutation of catalytic beta chains.[2:2][4:3]
In healthy brain tissue, PSMA2-containing proteasomes clear oxidized proteins, synaptic proteins requiring turnover, and damaged components generated during metabolic stress.[2:3][6] This supports:
Proteasome function is closely integrated with lysosomal-autophagic systems; when UPS activity drops, autophagy compensation often increases but may fail in aged or diseased neurons.[2:5][8]
Proteasome dysfunction is repeatedly observed in AD cortex and hippocampus, where it can exacerbate tau and amyloid-related proteotoxicity.[3:1][7:1] Reduced UPS flux can increase persistence of misfolded intermediates, reinforcing synaptic loss and inflammatory signaling.[2:6][8:1]
In PD, alpha-synuclein pathology and mitochondrial stress converge with UPS insufficiency in dopaminergic neurons.[3:2][9] Experimental proteasome inhibition induces features of nigrostriatal degeneration, supporting a mechanistic role for impaired proteasomal processing.[9:1][10]
ALS/FTD models show broad proteostasis pressure involving RNA-binding protein aggregates, stress granules, and impaired protein clearance pathways.[8:2][11] PSMA2 should be interpreted as part of this shared system vulnerability architecture.
Potential applications for PSMA2-centered biology include:
A major translational challenge remains achieving sustained proteasome enhancement without unintended effects on normal signaling and immune-relevant protein processing.[5:2][8:4]
The study of Psma2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Collins GA, Goldberg AL. The Logic of the 26S Proteasome. Cell. 2017. ↩︎ ↩︎
Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. Nature Reviews Molecular Cell Biology. 2019. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. Journal of Neurochemistry. 2000. ↩︎ ↩︎ ↩︎
Rousseau A, Bertolotti A. Regulation of proteasome assembly and activity in health and disease. Nature Reviews Molecular Cell Biology. 2018. ↩︎ ↩︎ ↩︎ ↩︎
Livneh I, Cohen-Kaplan V, Cohen-Rosenzweig C, Avni N, Ciechanover A. The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death. Cell Research. 2016. ↩︎ ↩︎ ↩︎
Tai HC, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nature Reviews Neuroscience. 2008. ↩︎ ↩︎
Dantuma NP, Bott LC. The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. Frontiers in Molecular Neuroscience. 2014. ↩︎ ↩︎
Thibaudeau TA, Anderson RT, Smith DM. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. Nature Communications. 2018. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
McNaught KSP, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Annals of Neurology. 2004. ↩︎ ↩︎
McNaught KSP, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Annals of Neurology. 2004. ↩︎
Yerbury JJ, Ooi L, Dillin A, et al. Walking the tightrope: proteostasis and neurodegenerative disease. Journal of Clinical Investigation. 2016. ↩︎ ↩︎